SMV + SOF With/Without RBV for IFN-II Patients With CHC
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/21/2018 |
| Start Date: | October 2014 |
| End Date: | June 2016 |
Simeprevir (SMV) + Sofosbuvir (SOF) With or Without Ribavirin (RBV) for Interferon-intolerant or Ineligible (IFN-II) Patients With Chronic Hepatitis C (CHC)
Prior trials have shown that many G1 CHC patients are ineligible or intolerant to pegylated
(PEG)-based regimens due to prior severe side effects, worsening of cytopenias, exacerbation
of underlying psychiatric disorders, or autoimmune disorders. These patients will not be
candidates for treatment with the approvals of SMV and SOF in early 2014 due to the
combination with PEG-regimens. Results of the COSMOS study suggest that these patients are
likely to have excellent responses to SMV+SOF with or without RBV with 12 weeks of therapy,
and that 24 weeks are unnecessary. This trial is designed to rapidly enroll and be completed
in order to confirm this hypothesis.
(PEG)-based regimens due to prior severe side effects, worsening of cytopenias, exacerbation
of underlying psychiatric disorders, or autoimmune disorders. These patients will not be
candidates for treatment with the approvals of SMV and SOF in early 2014 due to the
combination with PEG-regimens. Results of the COSMOS study suggest that these patients are
likely to have excellent responses to SMV+SOF with or without RBV with 12 weeks of therapy,
and that 24 weeks are unnecessary. This trial is designed to rapidly enroll and be completed
in order to confirm this hypothesis.
Inclusion Criteria:
1. Targeted at least 20% enrollment of patients with cirrhosis
2. Adults >/= age 18 years.
3. Active infection with hepatitis C virus (HCV) genotype 1
4. Must have health insurance that covers therapy with SOF+RBV
5. Female patients of childbearing age must have a negative pregnancy test prior to
initiating therapy, use at least two effective methods of contraception during
treatment, and undergo monthly pregnancy tests.
6. Patients must be either IFN-ineligible due to psychiatric, autoimmune, neurological,
or other causes that are confirmed appropriate by the PI; OR,
7. IFN-intolerant due to flu-like symptoms, psychiatric problems, cytopenia or other
causes deemed appropriate by the PI.
Exclusion Criteria:
1. Presence of HIV co-infection
2. Presence of hepatocellular carcinoma (HCC)
3. Prior organ transplantation
4. Any history of hepatic decompensation
5. Patients taking any of the following medications:
- Anticonvulsants- Carbamazepine, Oxcarbazepine, Phenobarbital, or Phenytoin.
- Anti-infectives-erythromycin, clarithromycin, or telithromycin.
- Antifungals- systemic itraconazole, ketoconazole, posaconazole, fluconazole, or
voriconazole.
- Antimycobacterials- rifampin, rifabutin or rifapentine.
- Corticosteroids- systemic dexamethasone.
- Propulsives- Cisapride.
- Herbals- Milk thistle or St. John's Wart.
6. Patients that have been exposed to direct acting anti-viral agents
7. Patients with severe renal impairment (estimated Glomerular Filtration Rate (eGFR) <50
mL/min/1.73m2) or with end stage renal disease (ESRD).
8. Patients with platelet count <50 x109/L, Hemoglobin <10 g/dL, or Neutrophils <0.5
x109/L.
9. Women who are pregnant.
10. Men whose partners are pregnant or plan on becoming pregnant.
We found this trial at
3
sites
Scripps Clinic Scripps Clinic in Torrey Pines has been providing exceptional medical care to people...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials